Abstract: The present disclosure relates to techniques for anti-myopia visual display therapy using a simulated myopic blur. In one particular aspect, a method is provided that includes obtaining a pattern for a digital image, selecting a color channel of the digital image, applying a blur effect to the color channel that modifies the digital image to have a simulated blur, and providing anti-myopia visual display therapy to a subject using the modified digital image. The therapy comprises: (i) rendering the modified digital image on a display of a computing device within a visual environment of the subject, or (ii) placing the modified digital image within the visual environment of the subject, based on an optimal viewing time.

Abstract: The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.

Abstract: The present disclosure is directed to methods of tuning chromatic aberration of the eyes of a subject for the treatment of myopia. Refractive errors of an eye of the subject are assessed in the presence of one or more of red, blue, or green colored light, individually. A hybrid achromatic lens having a refractive portion and a diffractive portion is then designed, with the hybrid lens having a distribution of power varied between the refractive portion and diffractive portion. As such, the hybrid lens produces a state of chromatic aberration for the eyes of the subject capable of reducing or eliminating myopia advancement for the eyes of the subject.

Abstract: The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.

Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

Abstract: A computer-implemented method for facilitating opportunistic screening for cardiomegaly includes obtaining a set of computed tomography (CT) images. The set of CT images captures at least a portion of a heart of a patient, and the set of CT images is captured for a purpose independent of assessing cardiomegaly. The method further includes using the set of CT images as an input to an artificial intelligence (AI) module configured to determine a heart measurement based on CT image set input. The method also includes obtaining heart measurement output generated by the AI module and, based on the heart measurement output, classifying the patient into one of a plurality of risk levels for cardiomegaly. The classification is operable to trigger additional action based on the corresponding risk level for the patient.

Abstract: Various examples are provided related to catalytic nanofiber membrane assemblies or structures which can be used in plasma reactors. In one example, a three-dimensional (3D) catalytic structure includes nanofiber-based elements (NFBEs) and electrodes placed about the NFBEs with the NFBEs stacked between the electrodes. In another example, a plasma reactor includes a vessel containing the 3D catalytic structure where gas pressure in the vessel is less than 1 atmosphere.

Abstract: The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer.

Abstract: A method and computer-based system is provided that assists physicians in detecting early tumor growth and allowing modification of treatment to have a positive impact on medical management, patient morbidity, outcomes and survival times. The method comprises measuring tumor volumes from radiological images to predict growth by a statistical method. The methods allow detection of increases in tumor size earlier than is currently possible and, therefore, advantageous in modifying or optimizing treatment.

Abstract: A system can be configured to: (i) obtain a set of input images depicting one or more bodily structures of a patient; (ii) determine whether one or more key structures are represented within the set of input images by utilizing a key structure detection module; (iii) determine one or more key images of the one or more images of the set of input images by utilizing a key image localization module; (iv) determine key structure segmentation by utilizing a key structure segmentation module; (v) determine one or more patient condition metrics using the key structure segmentation; and (vi) generate a report associated with the patient based upon the one or more patient condition metrics, or generate an entry at one or more practitioner worklists based upon the one or more patient condition metrics.

Abstract: The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.

Abstract: Provided herein are compositions and methods for protein purification.

Abstract: Disclosed is a method for reducing metastasis and/or tumor growth in a subject with cancer by administering an effective amount of an inhibin antibody to the subject with cancer. In particular, the subject may have ovarian cancer and the administration of inhibin antibody may impair tumor growth.

Abstract: Methods for using BMP9 or an agonist thereof to reduce metastasis of cancer are disclosed. The method may include administering an effective amount of BMP9 or an agonist thereof to a subject in need thereof, to reduce metastasis of cancer. The subject may be a human.

Abstract: A majority of neuroendocrine (NE) cancers overexpress somatostatin receptors (SSTRs). Disclosed herein are anti-SSTR2 monoclonal antibodies, and antibody-drug conjugates (ADCs) for use as NE cancer targeting therapeutics. Also disclosed is an isolated nucleic acid encoding the disclosed antibodies, as well as nucleic acid vectors containing this isolated nucleic acid operably linked to an expression control sequence. Also disclosed are cells transfected with these vectors and the use of these cells to produce the disclosed recombinant antibodies. Also disclosed is a method of treating a neuroendocrine (NE) cancer in a subject, comprising administering to the subject an effective amount of the disclosed antibody conjugated to an anti-cancer agent.

Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.

Abstract: A preparing a purified population of single chain Mycobacterium smegmatis porins.

Abstract: A method for ascertaining pulmonary fibrosis disease progression or treatment response includes obtaining a first set of computed tomography (CT) images of a lung and determining a first Pulmonary Surface Index (PSI) score for the lung by detecting a first actual lung boundary of the lung within the first set of CT images, determining a first approximated lung boundary within the first set of CT images, and determining the PSI score using inputs based on the first actual lung boundary and the first approximated lung boundary. The method also includes obtaining a second set of CT images of the lung and determining a second PSI score for the lung using inputs based on a second actual lung boundary and a second approximated lung boundary. The method also includes assessing pulmonary fibrosis treatment response or disease progression based on the first PSI score and the second PSI score.

Abstract: Disclosed are synthetic apolipoprotein E-mimicking peptides, derivatives thereof, and related peptides, which are useful as therapeutic agents for reducing plasma cholesterol; synthetic methods of making the peptides; pharmaceutical compositions comprising the peptides, and methods of treating lipid and metabolic disorders using the disclosed synthetic apolipoprotein E-mimicking peptides and compositions thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.